{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:21:32Z","timestamp":1791055292902,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022BCA036"],"award-info":[{"award-number":["2022BCA036"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1205000"],"award-info":[{"award-number":["2023YFF1205000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070830"],"award-info":[{"award-number":["82070830"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2025.102136","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:56:02Z","timestamp":1760140562000},"page":"102136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study"],"prefix":"10.1016","volume":"31","author":[{"given":"Ziming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-775X","authenticated-orcid":false,"given":"Yunfei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-9002","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.aohep.2025.102136_bib0001","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0002","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.102136_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.aohep.2025.102136_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.aohep.2025.102136_bib0006","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14787210.2021.1840353","article-title":"Bacterial death from treatment with fluoroquinolones and other lethal stressors","volume":"19","author":"Drlica","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"15","key":"10.1016\/j.aohep.2025.102136_bib0007","doi-asserted-by":"crossref","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.aohep.2025.102136_bib0008","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2016.04.003","article-title":"Antibiotic-induced changes in the intestinal microbiota and disease","volume":"22","author":"Becattini","year":"2016","journal-title":"Trends Mol Med"},{"issue":"10","key":"10.1016\/j.aohep.2025.102136_bib0009","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/liv.15663","article-title":"Antibiotic use and development of nonalcoholic fatty liver disease: a population-based case-control study","volume":"43","author":"Ebrahimi","year":"2023","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2025.102136_bib0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.102136_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2023.109495","article-title":"Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction","volume":"123","author":"Brandt","year":"2024","journal-title":"J Nutr Biochem"},{"issue":"7","key":"10.1016\/j.aohep.2025.102136_bib0012","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1194\/jlr.M075713","article-title":"Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids","volume":"58","author":"Janssen","year":"2017","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.aohep.2025.102136_bib0013","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1172\/JCI129194","article-title":"The gut microbiome and metabolic syndrome","volume":"129","author":"Dabke","year":"2019","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.aohep.2025.102136_bib0014","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/AAC.01180-06","article-title":"Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis","volume":"51","author":"Kedar","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.aohep.2025.102136_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108593","article-title":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","volume":"254","author":"Lin","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"729","key":"10.1016\/j.aohep.2025.102136_bib0016","doi-asserted-by":"crossref","first-page":"eadf4428","DOI":"10.1126\/scitranslmed.adf4428","article-title":"Prospective study design and data analysis in UK Biobank","volume":"16","author":"Allen","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.aohep.2025.102136_bib0017","unstructured":"Biobank U. UK Biobank algorithmically defined outcomes (ADOs). Version 2.0. 2022."},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0018","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.aohep.2025.102136_bib0019","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.aohep.2025.102136_bib0020","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"issue":"7726","key":"10.1016\/j.aohep.2025.102136_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.aohep.2025.102136_bib0022","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamainternmed.2021.2738","article-title":"Longitudinal assessment of safety of femoropopliteal endovascular treatment with Paclitaxel-coated devices among Medicare beneficiaries: the SAFE-PAD study","volume":"181","author":"Secemsky","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.aohep.2025.102136_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/j.gastro.2021.09.070","article-title":"Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: a nationwide cohort study","volume":"162","author":"Park","year":"2022","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.aohep.2025.102136_bib0024","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.aohep.2025.102136_bib0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrendo.2014.210","article-title":"Antibiotics in early life and obesity","volume":"11","author":"Cox","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.aohep.2025.102136_bib0026","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"issue":"29","key":"10.1016\/j.aohep.2025.102136_bib0027","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.2174\/13816128113199990381","article-title":"Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"41","key":"10.1016\/j.aohep.2025.102136_bib0028","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0029","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2017.02.014","article-title":"Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD","volume":"67","author":"Luukkonen","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.102136_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.aohep.2025.102136_bib0031","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin-clavulanate-induced liver injury","volume":"61","author":"deLemos","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.aohep.2025.102136_bib0032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tox.2008.08.009","article-title":"Flucloxacillin-induced liver injury","volume":"254","author":"Andrews","year":"2008","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.aohep.2025.102136_bib0033","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin-induced liver injury","volume":"13","author":"Martinez","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2025.102136_bib0034","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1111\/bcp.15445","article-title":"Cloxacillin-induced acute vanishing bile duct syndrome: a case study and literature review","volume":"88","author":"Faragalla","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.aohep.2025.102136_bib0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.taap.2015.01.015","article-title":"Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis","volume":"283","author":"Woolbright","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.aohep.2025.102136_bib0037","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/apt.14678","article-title":"Review article: therapeutic bile acids and the risks for hepatotoxicity","volume":"47","author":"Ashby","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"39","key":"10.1016\/j.aohep.2025.102136_bib0038","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.3748\/wjg.v20.i39.14205","article-title":"Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease","volume":"20","author":"Paradies","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.102136_bib0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2018.11.020","article-title":"Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease","volume":"160","author":"Grattagliano","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.aohep.2025.102136_bib0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/atm-20-5110","article-title":"The role of bile acids in cholestatic liver injury","volume":"9","author":"Cai","year":"2021","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.aohep.2025.102136_bib0041","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102136_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-241071","article-title":"Flucloxacillin-induced liver injury in elderly patient","volume":"14","author":"Angheleanu","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12263-021-00703-6","article-title":"Gut microbiota in patients with obesity and metabolic disorders - a systematic review","volume":"17","author":"Xu","year":"2022","journal-title":"Genes Nutr"},{"issue":"4","key":"10.1016\/j.aohep.2025.102136_bib0044","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00281-022-00936-6","article-title":"The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts","volume":"44","author":"Liwinski","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102136_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","article-title":"Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.aohep.2025.102136_bib0046","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11154-023-09843-z","article-title":"Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies","volume":"24","author":"Jayachandran","year":"2023","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:43Z","timestamp":1780649563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125003618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268125003618"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102136","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102136"}}